MGX Live signaler | Maksimer profitt med Getagraph.com

SELG 136522 min ago

@ $12.23

Utstedt: 14 feb 2024 @ 19:22

Avkastning: -42.76%

Forrige signal: feb 13 - 20:08

Forrige signal: Kjøp

Avkastning: 5.43 %

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 22:00):

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States...

Stats
Dagens volum	52 467.00
Gjennomsnittsvolum	132 130
Markedsverdi	262.25M
Neste inntjeningsdato	( $0 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0140 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Novo Holdings A/s	Sell	147 415	SERIES B PREFERRED STOCK
2024-02-08	Novo Holdings A/s	Sell	691 760	SERIES B-1 PREFERRED STOCK
2024-02-08	Noonberg Sarah B.	Sell	0	Common Stock
2024-02-08	Borges Luis	Buy	0

INSIDER POWER
-100.00
Last 3 transactions
Buy: 0 \| Sell: 839 175

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: 0.11 (neutral)

Signal:(52.84) Neutral

Metagenomi, Inc. Common Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Metagenomi, Inc. Common Korrelasjon - Valuta/Råvare

0.42
( neutral )

-0.28
( neutral )

0.00
( neutral )

0.18
( neutral )

0.30
( neutral )

Financial Reports:

No articles found.

Metagenomi, Inc. Common Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Metagenomi, Inc. Common

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.